Log in to search using one of your social media accounts:


PhRMA, member companies and NIH create public-private partnership for immuno-oncology

The rapid pace of scientific advances has helped usher in anew era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took asignificant step in advancing this new era by partnering with PhRMA and nine of its member companies to create the Partnership for Accelerating Cancer Therapies (PACT), a five-year research collaboration totaling $215 million as part of the Cancer Moonshot initiative. This public-private partnership will be managed by the Foundation for the National Institutes of Health.
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development cancer Source Type: news

Related Links:

Publication date: Available online 14 December 2017 Source:Egyptian Journal of Medical Human Genetics Author(s): Mohanan Geetha Gopisankar, A. Surendiran Oncolytic virotherapy is a new modality of cancer treatment which uses competent replicating viruses to destroy cancer cells. This field progressed from earlier observations of accidental viral infections causing remission in many malignancies to virus drugs targeting and killing cancer cells. More competent and specific viruses which attack tumor cells but not healthy cells could be made with advancements in the field of genetic engineering. Studying virus as a drug has...
Source: Egyptian Journal of Medical Human Genetics - Category: Genetics & Stem Cells Source Type: research
We describe the clinicopathologic features of 17 patients who had a hematologic malignancy of various types, were treated, and subsequently developed a lymphoproliferative disorder (LPD). There were 10 men and 7 women with a median age of 59 years (range, 36 to 83 y). The primary hematologic neoplasms included: 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, 3 plasma cell myeloma, 2 acute monoblastic leukemia, and 1 case each of mixed-phenotype acute leukemia, chronic myeloid leukemia, splenic marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, T-cell prolymphocytic leukemia, and peripheral...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
Conclusions: Taken together, the results provide insight into the biological and clinical potential of targeted AMO-21 and 5-Fu co-delivery using modified trastuzumab for GC treatment.Cell Physiol Biochem 2017;44:2158 –2173
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Conclusion: Collectively, our results demonstrate that Hippo-Yap can serve as a tumor promoter in human rectal cancer and acts by restricting JNK/Drp1/mitochondrial fission/ HtrA2/Omi, with potential implications for new approaches to human rectal cancer therapy.Cell Physiol Biochem 2017;44:2073 –2089
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
(Harvard Medical School) Survival benefits of many cancer drug combinations are not due to drug synergy, but to a form of " bet hedging. " Combination treatment gives each patient multiple chances of responding to at least one drug, increasing measures of survival within patient populations. Findings suggest new ways to interpret clinical trial data, identify truly synergistic drug pairings and improve the design of combination therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In the past decade, the resurgence of immunotherapy has changed the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed death ligand-1 on tumors cells are currently utilized in the management of several cancers. These agents are double-edged sword with the positive effect being robust antitumor response but on the other side they can throttle up the normal immunologic homeostasis in a negative way, leading to adverse autoimmune toxicities. These adverse toxicities are frequent if patients have active autoimmune disorders. Here, we ...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Case Reports Source Type: research
Publication date: January 2018 Source:Biomedicine & Pharmacotherapy, Volume 97 Author(s): Sahar Bayat, Mahmoud Shekari Khaniani, Jalal Choupani, Mohammad Reza Alivand, Sima Mansoori Derakhshan Epigenetics is independent of the sequence events that physically affect the condensing of chromatin and genes expression. The unique epigenetic memories of various cells trigger exclusive gene expression profiling. According to different studies, the aberrant epigenetic signatures and impaired gene expression profiles are master occurrences in cancer cells in which oncogene and tumor suppressor genes are affected. Owing to the ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Abstract The plant pentacyclic alkaloid camptothecin and its structural analogs were extensively studied. These compounds are interesting due to the antitumor activity associated with their ability to inhibit topoisomerase I in tumor cells. During the last decades of the 20th century, a large number of the silicon‐containing camptothecins (silatecans) were synthesized. 7‐tert‐Butyldimethylsilyl‐10‐hydroxy‐camptothecin (DB‐67 or AR‐67) has enhanced lipophilicity and demonstrates a antitumor activity superior to its carbon analog. To date, certain silatecans are under clinical trials and their ultimate role i...
Source: Archiv der Pharmazie - Category: Drugs & Pharmacology Authors: Tags: REVIEW ARTICLE Source Type: research
AbstractRNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, incl...
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 November 2017 Source:Seminars in Cancer Biology Author(s): K. Vermaelen, A. Waeytens, O. Kholmanskikh, M. Van den Bulcke, E. Van Valckenborgh Immunotherapies, specifically checkpoint inhibitors, are becoming an important component in cancer care with the most application now in melanoma and lung cancer patients. Some drawbacks that converge with this new evolution are the rather low response rates to these drugs and their high cost with a significant economic impact on the health care system. These major challenges can likely be circumvented by implementing a “personalized immun...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | National Institutes of Health (NIH) | Partnerships | Pharmaceuticals